Please check your internet connection and try again.
# Piperacillin/Tazobactam
## Overview
Piperacillin/tazobactam is a combination antibiotic consisting of piperacillin, a penicillin-class beta-lactam antibiotic, and tazobactam, a beta-lactamase inhibitor. It has a broad spectrum of activity against many Gram-positive, Gram-negative, and anaerobic bacteria.
## Primary Indications
* Complicated intra-abdominal infections
* Complicated skin and skin structure infections (including diabetic foot infections)
* Community-acquired pneumonia
* Nosocomial pneumonia (hospital-acquired pneumonia, ventilator-associated pneumonia)
* Febrile neutropenia (empiric treatment)
* Complicated urinary tract infections, including pyelonephritis
## Adult Dosing
* **Standard Dosing:** 3.375 grams (3g piperacillin / 0.375g tazobactam) to 4.5 grams (4g piperacillin / 0.5g tazobactam) every 6 or 8 hours intravenously (IV).
* **Severe Infections/High Inoculum:** Doses up to 4.5 grams every 4 hours IV may be considered, particularly for infections due to less susceptible organisms or in critically ill patients. Doses should not exceed 18 grams of piperacillin (or 16g piperacillin component) per day.
* **Duration:** Typically 7-14 days, depending on infection severity and patient response.
## Pediatric Dosing
* **Patients ≥ 12 years:** Same as adult dosing.
* **Patients < 12 years:** Dosing is based on piperacillin component weight-based.
* **General Infections:** 80 mg piperacillin/10 mg tazobactam per kg per dose, administered every 6 hours IV.
* **Severe Infections (e.g., nosocomial pneumonia, febrile neutropenia):** 100 mg piperacillin/12.5 mg tazobactam per kg per dose, administered every 6 hours IV.
* **Maximum Pediatric Dose:** Generally not to exceed the maximum adult dose.
* **Infants < 4 months:** Use is generally not recommended due to lack of established safety and efficacy data. If used, close monitoring for toxicity is warranted.
## Dose Adjustments
* **Renal Impairment (CrCl < 20 mL/min):** Reduce dose frequency. Standard regimen (e.g., 3.375g q8h) should be given every 12 hours. For higher frequency regimens (e.g., 4.5g q6h), reduce to 2.25g every 8 hours or 4.5g every 12 hours. Intermittent hemodialysis: administer dose after dialysis and reduce frequency to every 12 hours.
* **Renal Impairment (CrCl 20-50 mL/min):** Dose frequency may need adjustment, consult specific guidelines or prescribing information.
* **Hepatic Impairment:** No dose adjustment typically required.
## Contraindications
* Hypersensitivity to piperacillin, tazobactam, other penicillinase-resistant penicillins, or any component of the product.
* History of a severe allergic reaction (e.g., anaphylaxis) to a beta-lactam antibiotic.
## Adverse Effects
* **Common:** Diarrhea, nausea, vomiting, rash, headache, insomnia, constipation, abdominal pain, elevated liver enzymes (AST, ALT).
* **Serious:** Hypersensitivity reactions (including anaphylaxis), Clostridioides difficile-associated diarrhea, seizure (especially with high doses or renal impairment), neutropenia, thrombocytopenia, interstitial nephritis, liver toxicity.
## Key Drug Interactions
* **Probenecid:** May increase and prolong piperacillin/tazobactam serum concentrations.
* **Neuromuscular blocking agents:** Piperacillin may prolong the action of vecuronium.
* **Warfarin:** May decrease the effect of warfarin; monitor INR closely.
* **Methotrexate:** May decrease methotrexate clearance; monitor methotrexate levels.
* **Live bacterial vaccines:** May decrease efficacy.
## Monitoring
* Renal function (baseline and periodically).
* Liver function tests (baseline and periodically).
* Complete blood count (CBC) with differential (especially for prolonged therapy or suspected hematologic toxicity).
* Signs and symptoms of hypersensitivity reactions.
* Signs and symptoms of C. difficile infection.
* Culture and sensitivity results to guide therapy and de-escalation.
## Clinical Pearls
* Piperacillin/tazobactam is generally administered by IV infusion over 30 minutes. Extended infusions (e.g., over 4 hours) may be considered in certain critically ill patients to optimize pharmacokinetic/pharmacodynamic targets.
* Tazobactam expands the spectrum of piperacillin by inhibiting many beta-lactamases, including some extended-spectrum beta-lactamases (ESBLs), but resistance can still occur.
* Monitor for signs of electrolyte imbalance, especially hypernatremia, due to the high sodium content of the reconstituted solution.
* Dosing for febrile neutropenia is often guided by institutional protocols and patient risk factors.
***
*Please verify current prescribing information and institutional protocols before administering any medication. This information is intended as a reference and does not replace professional clinical judgment.*
